Switching From Wegovy to Zepbound (or Back): 3 Things to Settle First

Switching between Wegovy and Zepbound is common and can be done safely, but three things should be settled first: why you’re switching, how your body handles each drug, and which dose of the new one is about as strong as your current dose. Zepbound is stronger on paper, but the stronger drug isn’t always the one that works best for you.

Zepbound vs. Wegovy: how they differ

Wegovy is semaglutide. It acts on one gut hormone receptor, GLP-1. Zepbound is tirzepatide. It acts on GLP-1 and a second receptor, GIP, so it’s called a dual agonist. Both are FDA-approved for long-term weight management. The same drug in Zepbound is sold as Mounjaro for type 2 diabetes, and the drug in Wegovy is sold as Ozempic.

In the only head-to-head trial, people lost about 20% of their body weight on Zepbound and about 14% on Wegovy’s standard dose over 72 weeks.

1. Why you’re switching

Maybe you have side effects you can’t get past. Maybe you’re not getting results, or your insurance changed which drug it covers. The reason matters because it tells your doctor what the switch has to fix.

2. How your body responds

Average trial results don’t predict how one person will do. Some people don’t feel right on Zepbound and do better on Wegovy, and the other way around. The reason is the dose climb: you usually have to step the dose up over time to get the full effect. If a medicine makes you feel sick, you can’t go up, and it never gets a chance to work. The right drug is the one your body handles well enough to reach a dose that works, and the only way to know is to try.

3. The dose you start on

The doses on Wegovy and Zepbound don’t line up. The same number of milligrams means something different on each, and neither label has a chart for switching. So your doctor has to choose a dose of the new drug that’s about as strong as what you take now. Too high and your stomach may rebel. Too low and your hunger may come back. The goal is to start about even. You can always go up from there.

Two questions to ask before you switch

• What dose of the new drug is about as strong as the one I’m on now?
• For someone like me, how do the two compare?

Sources

• Aronne et al., New England Journal of Medicine, 2025 (SURMOUNT-5): tirzepatide vs. semaglutide head to head in adults with obesity, 72 weeks
• Zepbound prescribing information: how tirzepatide works and its dosing
• Wegovy prescribing information: semaglutide dosing